Market Newsdesk

BOSTON, Nov. 19, 2020 /PRNewswire/ — Eaton Vance Senior Income Trust (NYSE: EVF) (the “Fund”) announced today the results of its Annual Meeting of Shareholders held on November 12, 2020 (the “Meeting”) for the election of four members of the Fund’s board of trustees (“Board”) to serve three-year terms ending in 2023. 

Incumbent Class I Trustee Valerie A. Mosley was elected to a new term as a Class I Trustee by the Fund’s Auction Preferred shareholders.  Incumbent Class I Trustees Thomas E. Faust Jr., Cynthia E. Frost and Susan J. Sutherland will continue to serve as Class I Trustees because none of the candidates presented for election by the Fund’s Common and Auction Preferred shareholders received the requisite vote.  Pursuant to the Fund’s Amended and Restated By-Laws, when none of such candidates receive the requisite vote, the incumbent Trustees remain in office for a new three-year term.    

The individuals named on the Fund’s proxy cards proposed to adjourn the Meeting to permit further solicitation with respect to the three Class I Trustee positions subject to election by the Common and Auction Preferred shareholders (“Adjournment”).  Such individuals believed that further solicitation of proxies would have resulted in a higher vote total.  A representative of Saba Capital Management, L.P. (“Saba”), as proxy for votes solicited for the Meeting on the gold proxy card supported by Saba, voted against the proposed Adjournment, resulting in the proposed Adjournment not being approved. 

The vote tabulations, as certified by the Fund’s independent inspector of election, First Coast, Results, Inc., will be published in the Fund’s next report to shareholders. 

The Fund’s investment adviser is Eaton Vance Management, a subsidiary of Eaton Vance Corp.  Eaton Vance Corp. (NYSE: EV) provides advanced investment strategies and wealth management solutions to forward-thinking investors around the world. Through principal investment affiliates Eaton Vance Management, Parametric, Atlanta Capital, Calvert and Hexavest, the Company offers a diversity of investment approaches, encompassing bottom-up and top-down fundamental active management, responsible investing, systematic investing and customized implementation of client-specified portfolio exposures. As of September 30, 2020, Eaton Vance had consolidated assets under management of $517.0 billion. For more information, visit eatonvance.com.

Shares of closed-end funds often trade at a discount from their net asset value. The market price of Fund shares may vary from net asset value based on factors affecting the supply and demand for shares, such as Fund distribution rates relative to similar investments, investors’ expectations for future distribution changes, the clarity of the Fund’s investment strategy and future return expectations, and investors’ confidence in the underlying markets in which the Fund invests. Fund shares are subject to investment risk, including possible loss of principal invested. The Fund is not a complete investment program and you may lose money investing therein. An investment in the Fund may not be appropriate for all investors. Before investing, prospective investors should consider carefully the Fund’s investment objective, risks, charges and expenses.

This press release is for informational purposes only and is not intended to, and does not, constitute an offer to purchase or sell shares of the Fund. Additional information about the Fund, including performance and portfolio characteristic information, is available at www.eatonvance.com.

Statements in this press release that are not historical facts are forward-looking statements as defined by the U.S. securities laws. You should exercise caution in interpreting and relying on forward-looking statements because they are subject to uncertainties and other factors which are, in some cases, beyond the Fund’s control and could cause actual results to differ materially from those set forth in the forward-looking statements.

View original content:http://www.prnewswire.com/news-releases/results-of-annual-shareholder-meeting-of-eaton-vance-senior-income-trust-301177084.html

SOURCE Eaton Vance Management

NEW YORK, Nov. 19, 2020 /PRNewswire/ — Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) (“Actinium”) today announced the appointment of Avinash Desai, MD, to the position of Executive Vice President of Clinical Development, Operations and Medical Affairs, effective immediately.  In this role, Dr. Desai will lead Actinium’s medical affairs strategies for Iomab-B to the transplant and hematology communities as well as for Actimab-A to the hematologist communities. In addition, he will play an integral role in the strategic development of the Iomab-B clinical programs.

Dr. Mark Berger, Actinium’s Chief Medical Officer, said, “We are pleased to have Dr. Desai join the leadership team.  His expertise in medical affairs and clinical strategy will be a great asset for Actinium as we advance the SIERRA trial through its final phase and prepare for next steps.  Avi’s experience working with hematology and oncology clinical candidates through registrational studies and successful commercial launches will be helpful as we continue to advance our CD45 and CD33 programs towards multiple registrational studies and prepare for the BLA filing and commercialization of our late-stage asset, Iomab-B.”

“I am thrilled to join Actinium as EVP of Clinical Development, Operations and Medical Affairs at such a crucial point for the Company,” stated Dr. Desai.  “Recent clinical achievements with Iomab-B and Actimab-A uniquely position the Company to make a real impact in targeted conditioning and the treatment of patients with relapse or refractory Acute Myeloid Leukemia (R/R AML).  I look forward to working with the leadership team in advancing these product candidates to patients who continue to have a significant unmet need despite recently approved therapeutic agents.”  

Dr. Desai is an industry veteran in the hematology and oncology field, most recently serving as Vice President, Head of U.S. Medical Affairs – Oncology at Glaxo Smith Kline (GSK). Over the course of his twenty-five-year career, Dr. Desai has successfully designed and implemented clinical development, U.S. and global medical affairs, and life cycle management plans for a variety of pharmaceutical products. This has included participation in multiple INDs, NDAs, and sNDA submissions and efficiently managing the product Scientific Advisory Boards (SAB) and Data and Safety Monitoring Boards (DSMB) for hematology, oncology and therapeutic candidates.  At GSK, he established the U.S. medical affairs oncology team that oversaw the launch readiness plans for three novel oncology products—Blenrep® in multiple myeloma, Zejula® in ovarian cancer, and dostarlimab in endometrial cancer. In addition to GSK, Dr. Desai has overseen the clinical development, implementation and delivery of oncology life cycle management plans for various oncology therapies at several leading global pharmaceutical companies, including Eli Lilly & Company (Lilly), Janssen Pharmaceuticals, Inc. and Takeda, Inc.  Prior to GSK, he was the VP of Global Medical Affairs at Lilly, during which time he oversaw the global medical affairs team for Lilly’s GI Oncology portfolio.  Earlier in his career, Dr. Desai contributed to the approval of Janssen’s myeloma drug Darzalex® (daratumumab) and leading and strategically executing medical affairs activities globally for Velcade® (bortezomib).  Prior to Janssen, Dr. Desai was responsible for the international development of oncology products in solid tumors and hematological malignancies at Sanofi, where he successfully executed pivotal trials that led to NDA submission for Jevtana® (cabazitaxel).

Sandesh Seth, Actinium’s Charmain and Chief Executive Officer, stated “As Actinium approaches key milestones for Iomab-B and Actimab by year-end and sets the stage for a milestone rich 2021, Dr. Desai’s impressive experience in medical affairs, clinical development and operational management will be extremely valuable.  Avi’s successful track record and demonstrated operational excellence will greatly benefit Actinium as we prepare for the commercialization of Iomab-B and the registrational trials for our CD33 program in R/R AML.  Avi’s deep experience gained through multiple commercial launches will be important in guiding our efforts as we further expand our medical affairs activities in the top tertiary care hospitals that treat R/R AML to support Iomab-B and Actimab-A and we look forward to his contributions to our leadership team.”

About Actinium Pharmaceuticals, Inc. (NYSE: ATNM)

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation.  Actinium’s lead application for our ARCs is targeted conditioning, which is intended to selectively deplete a patient’s disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities.  With our ARC approach, we seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently.  Our lead product candidate, I-131 apamistamab (Iomab-B) is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning.  The SIERRA trial is over seventy-five percent enrolled and positive single-agent, feasibility and safety data has been highlighted at ASH, TCT, ASCO and SOHO annual meetings.  More information on this Phase 3 clinical trial can be found at sierratrial.com. I-131 apamistamab will also be studied as a targeted conditioning agent in a Phase 1 study with a CD19 CAR T-cell Therapy with Memorial Sloan Kettering Cancer Center and Phase 1/2 anti-HIV stem cell gene therapy with UC Davis.  In addition, we are developing a multi-disease, multi-target pipeline of clinical-stage ARCs targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma.  Ongoing combination trials include our CD33 alpha ARC, Actimab-A, in combination with the salvage chemotherapy CLAG-M and the Bcl-2 targeted therapy venetoclax.  Underpinning our clinical programs is our proprietary AWE (Antibody Warhead Enabling) technology platform.  This is where our intellectual property portfolio of over 100 patents, know-how, collective research and expertise in the field are being leveraged to construct and study novel ARCs and ARC combinations to bolster our pipeline for strategic purposes.  Our AWE technology platform is currently being utilized in a collaborative research partnership with Astellas Pharma, Inc. Website: https://www.actiniumpharma.com/

Forward-Looking Statements for Actinium Pharmaceuticals, Inc. 

This press release may contain projections or other “forward-looking statements” within the meaning of the “safe-harbor” provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management’s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium’s products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium’s filings with the Securities and Exchange Commission (the “SEC”), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

Contacts:

Investors:
Clayton Robertson
Actinium Pharmaceuticals, Inc. 
[email protected]

Hans Vitzthum

LifeSci Advisors, LLC
[email protected] 
(617) 430-7578

View original content to download multimedia:http://www.prnewswire.com/news-releases/actinium-strengthens-leadership-team-with-appointment-of-dr-avinash-desai-as-executive-vice-president-of-clinical-development-operations-and-medical-affairs-301177003.html

SOURCE Actinium Pharmaceuticals, Inc.

MARLBOROUGH, Mass., Nov. 19, 2020 /PRNewswire/ — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that its chief executive officer, Dr. Gerrit Dispersyn, will present at the upcoming 3rd Annual Evercore ISI HealthCONx Conference, which is being held virtually this year from December 1-3, 2020.

https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg

Dr. Dispersyn is scheduled to participate in a fireside chat on Thursday, December 3^rd, at 3:05 p.m. ET. Interested parties may access a live webcast of the presentation at https://wsw.com/webcast/evercore11/phio/2360016.

An archived version of the webcast will be made available on the “Investors – Events and Presentations” section of the Company’s website after the live event.

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company’s efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company’s website, www.phiopharma.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. These statements are based only on our current beliefs, expectations and assumptions regarding the impact to our business and operations by the recent coronavirus outbreak, results from our preclinical and clinical activities, the development of our product candidates, the ability to obtain future financing, the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption “Risk Factors” and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.

Contact Phio Pharmaceuticals Corp.
[email protected] 

Investor Contact
Ashley R. Robinson 
LifeSci Advisors
[email protected] 

 

View original content:http://www.prnewswire.com/news-releases/phio-pharmaceuticals-to-participate-in-the-3rd-annual-evercore-isi-healthconx-conference-301176360.html

SOURCE Phio Pharmaceuticals Corp.

TSX-V:  GBR                                                                             

VANCOUVER, BC, Nov. 19, 2020 /PRNewswire/ – Great Bear Resources Ltd. (the “Company” or “Great Bear”) (TSXV: GBR) (OTCQX: GTBAF) is pleased to announce the nomination of Paula Rogers to its Board of Directors, and invites interested shareholders to attend a Company webinar on November 30^th, 2020.

Ms. Rogers has over 25 years experience working with international public companies, with a special focus on debt and equity-based project financing in the mining industry, corporate governance, financial reporting and tax strategy.  She holds a B. Comm. degree from the University of British Columbia and is a Chartered Professional Accountant.

Ms. Rogers’ past roles include Vice President and Treasurer with Goldcorp Inc. and Treasurer with Wheaton River Minerals Ltd., where she completed over $3 billion of equity and debt based project financings including the Pueblo Viejo mine in the Dominican Republic (operated by Barrick Gold Corp. and Newmont Corp.).  She was also Treasurer of Silver Wheaton Corp., where she oversaw all silver contract purchases and sales.

Most recently she has been Chair of the Board and Director of Alio Gold Inc., which recently merged with Argonaut Gold Inc., where she is now a Director. 

Chris Taylor, President and CEO of Great Bear said, “Great Bear management is very pleased to nominate Paula Rogers to our Board of Directors, and recommend shareholders approve her nomination at our December Annual General Meeting.  Paula was an integral member of the core foundational teams at Goldcorp and Silver Wheaton.  She is an expert on the types of advanced project financing and governance tasks that Great Bear has before us as we continue to advance our flagship Dixie Project.  We at Great Bear feel privileged to have the opportunity to work with such a highly respected member of the Canadian mining community and anticipate our shareholders will receive strong long-term benefits through Ms. Rogers’ experience.”

Live Investor Webinar

A live Great Bear webinar will take place on Monday, November 30^th at 9:00am PST/12:00pm EST.  Chris Taylor and Bob Singh will be available to answer questions following the presentation.  Online registration and participation details may be found at the following link:

https://us02web.zoom.us/webinar/register/WN_XCKIzugJTFOETejNpYYGyg

For those unable to participate, a recording of the webinar will be posted to the Company’s web site following the live broadcast.

The webinar will discuss the Company’s ongoing progress involving detailed three dimensional modeling of the geology and gold zones at the Dixie project.

Regional Project Acquisition

The Company also announces acquisition of an additional claim package as part of its regional exploration program.  The “Red Lake North” (or “RLN”) property consists of 3,220 hectares of mineral claims located in what are interpreted to be the Woman Lake and Flat Lake assemblages of the Balmer Sequence, approximately 70 kilometres northeast of Red Lake.  Figure 1.  Of importance, third party logging activities are planned for 2021 that will provide road access to the RLN property for the first time, facilitating low cost exploration.

Figure
1
: Great Bear’s Red Lake properties, showing the location of the new Red Lake North property.

The property hosts local D2 fold culminations which are important controls of gold mineralization elsewhere in the Red Lake area, and contain several gold-in-quartz vein type historical showings, including limited historical drilling.  The best results consist of generally less than 1 metre wide veins assaying up to approximately 20 – 25 g/t gold, described in historical reports (e.g. Flint Rock Mines Ltd., assessment files, Resident Geologist’s office, Red Lake. Fyon, A. J. and O’Donnell, L. 1986, O.G.S. M.P. 132, p. 269, 270, 274).

Great Bear can acquire a 100%, royalty-free interest in the RLN property through an option agreement with Perry English, Gravel Ridge Resources Ltd., and 1544230 Ontario Inc. (a company controlled by Perry English), whereby Great Bear will pay a total of $125,000 over a period of four years, and issue 10,000 shares to the vendors.  The agreement and the issuance of the shares are subject to TSX-V approval.

Details of Annual General Meeting

The Company’s Annual General Meeting (“AGM”) will be held at Suite 1020 – 800 West Pender Street, Vancouver, British Columbia, on Wednesday, December 15, 2020 at 2 pm Pacific Time. 

Due to ongoing concerns related to the spread of COVID-19, and in order to mitigate potential risks to the health and safety of the Company’s shareholders, employees, communities and other stakeholders, shareholders are encouraged not to attend the AGM in person.  Shareholders are strongly encouraged to vote on the matters before the meeting by proxy.  There are no assurances that the management or the Board will attend the meeting in person.  The Company requests that shareholders who wish to attend the meeting in person contact the Company in advance to make arrangements at [email protected].

The management of Great Bear is pleased to disclose the list of board nominees up for election at the at AGM, which includes the proposed addition of Paula Rogers:

Great Bear’s Vice President, Exploration Mr. R. Bob Singh, P.Geo. will not stand for re-election to his Board position in order to accommodate Ms. Rogers’ addition.  Mr. Singh will remain focused on directing the Company’s exploration activities.

About the Dixie Project

The Dixie Project is 100% owned, comprised of 9,140 hectares of contiguous claims that extend over 22 kilometres, and is located approximately 25 kilometres southeast of the town of Red Lake, Ontario. The project is accessible year-round via a 15 minute drive on a paved highway which runs the length of the northern claim boundary and a network of well-maintained logging roads.

The Dixie Project hosts two principal styles of gold mineralization:

• High-grade gold in quartz veins and silica-sulphide replacement zones (Dixie Limb, Hinge and Arrow zones). Hosted by mafic volcanic rocks and localized near regional-scale D2 fold axes. These mineralization styles are also typical of the significant mined deposits of the Red Lake district.

• High-grade disseminated gold with broad moderate to lower grade envelopes (LP Fault). The LP Fault is a significant gold-hosting structure which has been seismically imaged to extend to 14 kilometres depth (Zeng and Calvert, 2006), and has been interpreted by Great Bear to have up to 18 kilometres of strike length on the Dixie property. High-grade gold mineralization is controlled by structural and geological contacts, and moderate to lower-grade disseminated gold surrounds and flanks the high-grade intervals. The dominant gold-hosting stratigraphy consists of felsic sediments and volcanic units.

About Great Bear

Great Bear Resources Ltd. is a well-financed gold exploration company managed by a team with a track record of success in mineral exploration.  Great Bear is focused in the prolific Red Lake gold district in northwest Ontario, where the company controls over 330 km² of highly prospective tenure across 5 projects: the flagship Dixie Project  (100% owned), the Pakwash Property (earning a 100% interest), the Dedee Property (earning a 100% interest), the Sobel Property (earning a 100% interest), and the Red Lake North Property (earning a 100% interest) all of which are accessible year-round through existing roads.

Qualified Person and NI 43-101 Disclosure

Mr. R. Bob Singh, P.Geo, Director and VP Exploration, and Ms. Andrea Diakow P.Geo, Exploration Manager for Great Bear are the Qualified Persons as defined by National Instrument 43-101 responsible for the accuracy of technical information contained in this news release.

ON BEHALF OF THE BOARD

“Chris Taylor”                                  

Chris Taylor, President and CEO

Cautionary note regarding forward-looking statements

This release contains certain “forward looking statements” and certain “forward-looking information” as defined under applicable Canadian and U.S. securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “should”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or similar terminology. The forward-looking information contained herein is provided for the purpose of assisting readers in understanding management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes.

Forward-looking information are based on management of the parties’ reasonable assumptions, estimates, expectations, analyses and opinions, which are based on such management’s experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances, but which may prove to be incorrect.

Great Bear undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management’s best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.

View original content to download multimedia:http://www.prnewswire.com/news-releases/great-bear-nominates-paula-rogers-to-board-of-directors-announces-webinar-on-monday-november-30th-301176672.html

SOURCE Great Bear Resources Ltd.

BETHESDA, Md., Nov. 19, 2020 /PRNewswire/ — Walker & Dunlop, Inc. announced today that it will hold a virtual Investor Day on December 10, 2020 at 10:00 a.m. Eastern Time. The event will include an overview of the company’s vision for the next five years, featuring presentations and a Q&A session with members of Walker & Dunlop senior management.

Analysts and investors may access the webcast via the link below: https://walkerdunlop.zoom.us/webinar/register/WN_mFc4-mQFT7CvNuiuOh1_2g or by dialing +1-408-901-0584, Webinar ID 950 9227 0431, Passcode 857934. Presentation materials for the Investor Day will be posted to the Investor Relations section of the Company’s website. A webcast replay of the event will also be available on the Investor Relations section of the Company’s website at http://investors.walkerdunlop.com/.

About Walker & Dunlop

Walker & Dunlop (NYSE: WD), headquartered in Bethesda, Maryland, is one of the largest commercial real estate finance companies in the United States. The company provides a comprehensive range of capital solutions for all commercial real estate asset classes, as well as investment sales brokerage services to owners of multifamily properties. Walker & Dunlop is included on the S&P SmallCap 600 Index and was ranked as one of FORTUNE Magazine’s Fastest Growing Companies in 2014, 2017, and 2018. Walker & Dunlop’s 900+ professionals in 40 offices across the nation have an unyielding commitment to client satisfaction.

 

View original content:http://www.prnewswire.com/news-releases/walker–dunlop-announces-virtual-investor-day-details-301176632.html

SOURCE Walker & Dunlop, Inc.

HOUSTON, Nov. 19, 2020 /PRNewswire/ — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that new animal data has shown highly improved activity against acute myeloid leukemia (“AML”) when used in combination with the commonly used antileukemic drug Ara-C (also referred to as “cytarabine”) versus single agent.  The data is being presented at the 62nd Annual Meeting & Exposition of the American Society for Hematology (“ASH”) under the title: “High Efficacy of Liposomal Annamycin (L-ANN) in Combination with Cytarabine in Syngeneic p53-null AML Mouse Model.”

This study was conducted in a highly aggressive AML mouse model where median survival is approximately 13 days.  For animals treated with the combination of Annamycin and Ara-C, median survival ranged from 56 to 76 days, thus expanding median survival by 585%, with some animals being completely cured.  The conclusion of the study is that these experiments support initiation of clinical development of the combination of Annamycin and Ara-C in AML patients.

“This is a very important discovery that will most likely change the course of development for L-Annamycin,” commented Walter Klemp, Chairman and CEO of Moleculin. “While our current AML trials are encouraging and we are seeing significant activity with Annamycin as a single agent in relapsed AML patients, this data makes a compelling case that we should move as quickly as possible to begin a clinical trial in AML for the combination of Annamycin with Ara-C, something we are calling ‘AnnAraC.’  We believe the future for Annamycin just became even more promising.”

Mr. Klemp concluded: “Annamycin has already shown human activity as a single agent in its two Phase 1 AML clinical trials, including one complete response, and showing no signs of cardiotoxicity, unlike other anthracyclines.  And, it now appears, based on the observed synergy in vitro and confirmatory in vivo data, that the combination of Annamycin and Ara-C could be more effective in a clinical setting than Annamycin as a single agent.  This would be consistent with current practice to use Ara-C in combination with an anthracycline like Annamycin. The current first-line therapy for AML patients is the combination of an anthracycline and Ara-C in a regimen referred to as “7+3″ where Ara-C is administered daily for 7 days in parallel with 3 daily doses of an anthracycline.  Simply substituting the currently used anthracycline in a similar 7+3 regimen with Annamycin would represent a familiar and well-practiced treatment modality.  Beyond that, it would have the added advantages that Annamycin is active against tumor cells resistant to doxorubicin and, importantly, removes the concern for cardiotoxicity, a significant toxic side effect of currently used anthracyclines.”

The study abstract, as accepted by ASH, can be viewed at: https://ash.confex.com/ash/2020/webprogram/Paper143344.html

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses. The Company’s clinical stage drugs are: Annamycin, a Next Generation Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as WP1122 and related compounds capable of Metabolism/Glycosylation Inhibition.

For more information about the Company, please visit http://www.moleculin.com.

Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability of Annamycin to show safety and efficacy in AML patients, alone or in combination with Ara-C and the ability of the Company to receive regulatory authorization to begin a clinical trial for the combination of Annamycin and Ara-C. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin Biotech has attempted to identify forward-looking statements by terminology including ”believes,” ”estimates,” ”anticipates,” ”expects,” ”plans,” ”projects,” ”intends,” ”potential,” ”may,” ”could,” ”might,” ”will,” ”should,” ”approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (“SEC”) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC.  Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Contacts

James Salierno / Carol Ruth
The Ruth Group
973-255-8361 / 917-859-0214
[email protected]
[email protected]

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/moleculin-announces-new-data-demonstrating-synergistic-antitumor-activity-of-annamycin-combination-with-ara-c-in-aml-301176835.html

SOURCE Moleculin Biotech, Inc.

CENTREVILLE, Va., Nov. 19, 2020 /PRNewswire/ — Parsons Corporation (NYSE: PSN) announced today that the company has been selected to provide program management for the City and County of Denver’s Advanced Transportation and Congestion Management Technologies Deployment (ATCMTD) Connected Vehicle (CV) project. The company will oversee the data integration of Internet of Things devices at intersections and in city vehicles such as snowplows, improving situational awareness for drivers and operators of the Traffic Management Center (TMC).

“We share Denver’s view that the convergence of technology and innovation creates significant opportunity to improve daily life for its citizens,” said Tom Topolski, executive vice president, Connected Communities at Parsons. “Our experts have been deploying intelligent transportation solutions and smart city technologies for more than 30 years, and we look forward to working with Denver to ensure this deployment has the right technology to address traffic congestion and safety by connecting freight, fleet and pedestrians.”

The project includes technical project coordination, systems integration for the connected vehicle ecosystem, testing, deployment, cybersecurity and training for City and County of Denver personnel.

This work is part of a contract to provide numerous smart city solutions for the City and County of Denver’s Department of Transportation and Infrastructure, which aims to increase mobility and safety while reducing congestion and fighting climate change. The contract includes services ranging from systems engineering with agile development and intelligent systems to data systems and infrastructure, technical documentation and more.  

To learn more about Parsons’ Smart Cities expertise, visit Parsons.com/solutions/Connected-Communities/.

Parsons (NYSE: PSN) is a leading disruptive technology provider in the global defense, intelligence, and critical infrastructure markets, with capabilities across cybersecurity, missile defense, space, connected infrastructure, and smart cities. Please visit parsons.com, and follow us on LinkedIn and Facebook to learn how we’re making an impact.

Media Contact:                                                        
Bernadette Miller
+1 980.253.9781
[email protected]

Investor Relations Contact:
Dave Spille
+ 1 571.655.8264
[email protected]

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/parsons-accelerates-denvers-intelligent-transportation-transformation-301176829.html

SOURCE Parsons Corporation